REDOX POTENTIAL AND OXYGEN CONCENTRATION AS FACTORS IN THE SUSCEPTIBILITY OF HELICOBACTER-PYLORI TO NITROHETEROCYCLIC DRUGS

被引：68

作者：

SMITH, MA ^{[1
]}

EDWARDS, DI ^{[1
]}

机构：

[1] UNIV E LONDON, CHEMOTHERAPY RES UNIT, LONDON E15 4LZ, ENGLAND

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 1995年 / 35卷 / 06期

关键词：

D O I：

10.1093/jac/35.6.751

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Metronidazole sensitive (Mtz(S)) and resistant (Mtz(R)) strains of Helicobacter pylori were tested for their sensitivities to eleven nitroheterocyclic drugs of known reduction potential under a wide range of environmental conditions. Under microaerophilic conditions, Mtz(R) strains were sensitive to all the 2-nitroimidazoles, resistant to every 5-nitroimidazole, and slightly sensitive to the nitrothiazole, niridazole. Mtz(S) strains were sensitive to all the nitroimidazoles except for 4(5)-nitroimidazole which has the lowest redox potential of all the drugs investigated. Mtz(S) strains displayed the greatest sensitivity towards niridazole and satranidazole, the latter having the highest redox potential of the 5-nitroimidazoles. High and low oxygen tensions had no effect on the activity of the drugs but periods of anaerobic incubation caused resistant strains to become sensitive to the 5-nitroimidazoles. Superoxide dismutase and catalase were not induced by metronidazole and enzyme levels showed no correlation with resistance patterns. The results show that futile cycling does not occur in H. pylori and that the mechanism of action of the nitroimidazoles is related to their redox potential. Anaerobiosis abolishes resistance to metronidazole which suggests that it may be mediated through the activation of anaerobic metabolic pathways which function less under microaerophilic conditions or not at all.

引用

页码：751 / 764

页数：14

共 35 条

[1]

Adams G.E., Stratford I.J., Wallace R.G., Wardman P., Watts M.E., The toxidty of nitro compounds towards hypoxic mammalian cells in vitro: Dependence upon reduction potential, Journal of the National Cancer Institute, 64, pp. 555-560, (1980)

[2]

Bannatyne R.M., Jackowski J., Karmali M.A., Susceptibility of Campylobacter species to metronidazole, its bioactive metabolites and tinidazole, Infection, 15, pp. 457-458, (1987)

[3]

Bell G., Powell D., Burridge K.U., Pallecaros S.M.A., Jones P.H., Gant P.W., Et al., Experience with ‘triple’ anis-Helicobacter pylori eradication therapy: Side effects and the importance of testing the pre-treatment isolate for metronidazole resistance, Alimentary Pharmacology and Therapeutics, 6, pp. 427-435, (1992)

[4]

Bell G., Powell D.K., Weil J., Burridge S.M., Morden A., Harrison G., Et al., Helicobacter pylori treated with combinations of tripotassium dicitrato-bismuthate and metronidazole: Efficacy of different regimes and some observations on the emergence of metronidazole resistance, European Journal of Gastroenterology and Hepatology, 3, pp. 923-926, (1991)

[5]

Cederbrant G., Kahlmeter G., Ljungh A., Proposed mechanism for metronidazole resistance in Helicobacter pylori, Journal of Antimicrobial Chemotherapy, 29, pp. 115-120, (1992)

[6]

Claiborne A., Catalase activity, CRC Handbook of Methodsfor Oxygen Radical Research, pp. 283-284, (1985)

[7]

Clarke E.D., Wardman P., Goulding K.H., Anaerobic reduction of nitroimidazoles by reduced flavin mononucleotide and by xanthine oxidase, Biochemical Pharmacology, 29, pp. 2684-2687, (1980)

[8]

Dixon M.F., Campylobacter pylori and chronic gastritis, Campylobacter Pylori and Gastroduodenal Disease, (1989)

[9]

Edwards D.I., Nitroimidazole drugs—action and resistance mechanisms. I. Mechanism of action, Journal of Antimicrobial Chemotherapy, 31, pp. 9-20, (1993)

[10]

Edwards D.I., Nitroimidazoledrugs—action and resistance mechanisms. II. Mechanism of resistance, Journal of Antimicrobial Chemotherapy, 31, pp. 201-210, (1993)

← 1 2 3 4 →